01—Abstract
Summary
Summary of the 8-K filed February 10, 2025. Cited figures are marked; the original filing is the authoritative source.
On February 6, 2025, Cencora (COR) agreed to repurchase 204,491 of its common shares from Walgreens Boots Alliance Holdings LLC for approximately $50 milliona, at the same price at which Walgreens sold shares under a concurrent Rule 144 sale.
The repurchase closed February 10, 2025, was executed under Cencora's existing share repurchase program, and the shares will be held in treasury. The transaction is modest in size relative to Cencora's share count and revenue base, so it is unlikely to be financially material on its own. Its main significance is that it is a direct, negotiated buyback from a large holder that was unwinding its position alongside a series of variable prepaid forward (VPF) settlements.
The filing describes Walgreens' overall position as a block of stock being monetized through several channels at once. Simultaneously with the sale and repurchase, Walgreens settled certain VPF contracts early and had pledged shares returned. After these steps, Walgreens holds about 12,570,000 shares, roughly 6.5%b of Cencora's outstanding common stock, and the remaining shares stay pledged against other VPF contracts.
Investors should therefore view the overhang as partly reduced but not eliminated. The filing does not give a timetable for further sales or settlements of those remaining pledged shares.
For shareholders, the key takeaways are that Cencora used cash from its existing buyback authorization to retire a small block, reducing its outstanding share count by about 0.1%c, and that a large holder continues to reduce its exposure over time. The 8-K does not disclose the per-share price, the impact on earnings or guidance, or any change to capital return policy, so those details would need to come from the press release, the 10-K/10-Q, or management commentary.
02—Key points
Key Highlights
- Cencora repurchased 204,491 shares of common stock directly from Walgreens Boots Alliance Holdings LLC for approximately $50 million, closing on February 10, 2025.
- The repurchase price matched the per-share price at which Walgreens sold 1,081,885 shares under a concurrent Rule 144 sale on February 6, 2025.
- The buyback was funded under Cencora's existing share repurchase program, and the shares will be held in treasury rather than retired.
- The transaction coincided with Walgreens' early settlement of certain variable prepaid forward (VPF) contracts and the return of pledged shares.
- After these transactions, Walgreens owns about 12,570,000 shares, roughly 6.5% of Cencora's outstanding common stock, with remaining shares still pledged under other VPF contracts.
- Based on 193,712,591 shares outstanding after the repurchase, the deal represents a small reduction in share count (about 0.1%), so its effect on per-share metrics is likely immaterial.
- The 8-K does not disclose the per-share price, earnings impact, or any change to capital return guidance.
03—Questions
Frequently Asked Questions
Why did Cencora repurchase shares from Walgreens?
The filing presents the repurchase as a concurrent transaction tied to Walgreens' Rule 144 sale and its early settlement of VPF contracts. Cencora bought back a portion of the shares Walgreens was selling, which allowed the seller to exit part of its position with a known counterparty and provided Cencora a buyback at the market-linked sale price. The filing does not state Cencora's strategic rationale beyond executing under its existing program.
How much did the repurchase cost and how does it affect the share count?
Cencora paid approximately $50 million for 204,491 shares. Because the shares are held in treasury, they reduce shares outstanding, which the filing puts at 193,712,591 after the repurchase. The reduction is roughly 0.1% of the share count, a small effect on per-share figures.
Is Walgreens still a significant shareholder of Cencora?
Yes. After the Rule 144 sale, the VPF settlements, and the repurchase, Walgreens owns about 12,570,000 shares, or approximately 6.5% of outstanding common stock. The filing states that its remaining shares continue to be pledged to financial institutions under other existing VPF contracts, so further sales or settlements are possible.
What are variable prepaid forward contracts and why do they matter here?
A variable prepaid forward is a derivative-based arrangement in which a shareholder receives cash upfront in exchange for a future obligation to deliver shares, with the final amount tied to the stock price at settlement. Shares are typically pledged as collateral. Early settlement and share returns, as described here, reduce that collateral and the associated overhang, but the filing indicates that some pledged shares remain tied to other contracts.
Does this transaction change Cencora's financial outlook?
The 8-K does not discuss earnings, guidance, or capital allocation changes. Given the size of the roughly $50 million buyback relative to Cencora's revenue of more than $290 billion, the transaction is unlikely to be material to financial results. Investors should review the accompanying press release and subsequent filings for any management commentary.
04—Continue